Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 754 results for "lymphocyte count"

Coping mechanism suggests new way to make cancer cells more vulnerable to chemotherapies
HealthMediciNet.com

New Tool to Track Circulating Cancer Cells

Electron microscopic image of a single human lymphocyte. (Credit: Dr. Triche National Cancer Institute) Cancerous tumours are known to release cells into the bloodstream, and it is these circulating tumour cells or CTCs that are the sources of ... Medical Design Technology, 3 weeks ago

Characterizing Ph-Like Acute Lymphocytic Leukemia: A High-Risk Subgroup With Few Treatment Options

Treatment outcomes of patients with B-cell acute lymphocytic leukemia (B-ALL) vary according to age, with adult patients experiencing a poorer prognosis than pediatric patients. In a report published in Blood , Nitin Jain, MD, from the Department of ...
 ASH Clinical News1 day ago European Commission Grants Conditional Marketing Approval for AbbVie's VENCLYXTO (venetoclax) Monotherapy for..  ADVFN India1 month ago New Phase 2 Data Show Nearly Half of Patients with Relapsed/Refractory Marginal Zone Lymphoma (MZL) Respond to Treatment with Ibrutinib (IMBRUVICA®)  Nasdaq1 month ago RESONATE-2 Continues to Impress With Single-Agent Ibrutinib for CLL/SLL at 29 Months  American Journal of Managed Care1 month ago
[x]  

A rare cause of colonic thickening and lymphadenopathy

Advanced search A 73-year-old retired analytic chemist presented with 4 weeks of epigastric discomfort, weight loss and loose stools. His medical history revealed pancreatic insufficiency on the background of a pancreatic mass, which had resolved ...
 British Journal of the Gut1 month ago

Seattle Genetics Highlights Long-Term Follow-Up Data from ADCETRIS® (Brentuximab Vedotin) in T-Cell Lymphomas...

-Long-Term ADCETRIS Data Support Development Strategy to Establish ADCETRIS as Foundation of Care for CD30-Expressing Lymphomas- -ADCETRIS Pivotal Trial in Systemic Anaplastic Large Cell Lymphoma Shows Estimated Five-Year Survival Rate of 60 ...
 Freshnews.com1 month ago SEATTLE GENETICS : Highlights Long-Term Follow-Up Data from ADCETRIS® (Brentuximab Vedotin) in T-Cell Lymphomas at ASH Annual Meeting  4 Traders1 month ago Seattle Genetics and Bristol-Myers Squibb Highlight First Data from Phase 1/2 Study Evaluating...  Freshnews.com1 month ago
[x]  
LymphomaNewsToday.com

Genentech's Gazyva Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without...

First Phase III study to show superior progression-free survival compared to Rituxan-based standard of care treatment for most common slow-growing form of non-Hodgkin's lymphoma Results will be presented during the Plenary Scientific Session at ...
 Freshnews.com1 month ago Gazyva Shown to Outperform Rituxan in Phase 3 Trial in Follicular Lymphoma Patients  LymphomaNewsToday.com1 month ago Genentechs Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer  Newswire Today1 month ago Genentech???s Gazyva Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared To Rituxan  BioSpace1 month ago
[x]  

Data at ASH 2016 Show Strong, Lasting Efficacy of IMBRUVICA® (ibrutinib) Through Five Years of Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

SAN DIEGO AND RARITAN, N.J., Dec. 3, 2016 /PRNewswire/ -- Today, Janssen Research & Development, LLC (Janssen) announced the longest follow-up results to date of patients treated with IMBRUVICA® (ibrutinib) for chronic lymphocytic leukemia/small ...
 Yahoo! Finance1 month ago Janssen R&D Release: Data At American Society of Hematology 2016 Show Strong, Lasting Efficacy Of IMBRUVICA (Ibrutinib) Through Five Years Of Treatment For Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)  BioSpace1 month ago
[x]  

New Ibrutinib (IMBRUVICA®) Phase 2 Data Demonstrate Promise in Relapsed/Refractory Marginal Zone Lymphoma (MZL), a Rare, Incurable Type of Non-Hodgkin's Lymphoma

SAN DIEGO and RARITAN, N.J., Dec. 5, 2016 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced results from a Phase 2 study demonstrating a 48% overall response rate (ORR) as assessed by an Independent Review Committee (IRC) ...
 TickerTech.com1 month ago Janssen R&D Release: New Ibrutinib (IMBRUVICA) Phase 2 Data Demonstrate Promise In Relapsed/Refractory Marginal Zone Lymphoma (MZL), A Rare, Incurable Type Of Non-Hodgkin's Lymphoma  BioSpace1 month ago
[x]  

Karyopharm Presents Updated Phase 2 SAIL Relapsed/Refractory AML Clinical Data at the American Society of Hematology 2016 Annual Meeting

- Data Demonstrate Robust Response Rates Enabling Transplantation or Donor Lymphocyte Infusions in Patients with Heavily Pretreated Acute Myeloid Leukemia - NEWTON, Mass., Dec. 04, 2016 (GLOBE NEWSWIRE) Karyopharm Therapeutics Inc.
 Pharmacy Choice1 month ago Karyopharm Presents Updated Phase II SAIL Relapsed/Refractory AML Clinical Data At The American Society of Hematology 2016 Annual Meeting  BioSpace1 month ago
[x]  

The Hypothesis of the Human iNKT/Innate CD8(+) T-Cell Axis Applied to Cancer: Evidence for a Deficiency in Chronic Myeloid Leukemia

Introduction A hallmark of the antigen-specific T lymphocytes of the adaptive immune system is their capacity to remember foreign pathogens long after they are first encountered. Indeed, as far as the CD8 T cell pool is concerned, the main ...
 Frontiers in Neurorobotics2 days ago

New Acute Coronary Syndrome Study Findings Have Been Reported by Researchers at First Affiliated Hospital (Platelet-to-Lymphocyte Ratio Improves the...

New Acute Coronary Syndrome Study Findings Have Been Reported by Researchers at First Affiliated Hospital (Platelet-to-Lymphocyte Ratio Improves the Predictive Power of GRACE Risk Score for Long-Term Cardiovascular Events in Patients with Acute ...) ...
 Pharmacy Choice3 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less